David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
|Videos|April 5, 2016
Dr. John Mascarenhas on the COMFORT-I/II Studies for Ruxolitinib in Myelofibrosis
Author(s)John Mascarenhas, MD
The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis.
Advertisement
John Mascarenhas, MD, associate professor of medicine, Mount Sinai Hospital, discusses the COMFORT-I and COMFORT-II studies. The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis. In both studies ruxolitinib reduced splenomegaly and improving symptoms, mostly by down-modulating inflammitory cytokine signaling.
Advertisement
Related to this article
The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.
Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.
A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.
Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting pain post thoracotomy and reducing opioid use.
Rewriting the Playbook: How Biomarker-Driven Therapy Is Transforming Metastatic Prostate Cancer Care
For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
A Look Inside CONVERGE: Intratumoral Therapy Comes to Locally Advanced NSCLC
2
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
3
Navigating the Next Step After Progression in ccRCC
4
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
5